GlassScriptPhysician profile
Trusha P Bhatia
NPI 1164198891
$3,891.14
in general payments reported to CMS, 2019-2025
26 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.24 · 2022: $422 · 2023: $890 · 2024: $1,180 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,221 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,220.85 |
| Education | $217.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $644.60 | 2022-2025 | |
| Janssen Biotech, INC. | $534.20 | 2022-2025 | Tremfya |
| Ucb, INC. | $414.16 | 2024-2025 | Bimzelx |
| Incyte Corporation | $344.79 | 2023-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $287.12 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $233.79 | 2022-2024 | Ilumya, Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $212.91 | 2023-2025 | Nemluvio, Twyneo, Aklief |
| Dermavant Sciences, INC. | $182.72 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $135.17 | 2023-2025 | |
| Pfizer INC. | $129.73 | 2023 | |
| Arcutis Biotherapeutics, INC. | $114.81 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $101.57 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $93.39 | 2022-2025 | Adbry |
| Merz North America, INC. | $86.54 | 2022-2025 | |
| Amgen INC. | $58.82 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $56.81 | 2025 | Acthar |
| Organon LLC | $44.78 | 2024-2025 | Hadlima |
| Regeneron Healthcare Solutions, INC. | $42.47 | 2023-2025 | Dupixent |
| Genzyme Corporation | $29.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.69 | 2022 | |
| Merck Sharp & Dohme LLC | $26.48 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $23.11 | 2024 | Ycanth |
| Kyowa Kirin, INC. | $18.30 | 2024 | Poteligeo |
| Mayne Pharma Commercial LLC | $17.60 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.57 | 2024 | Cabtreo |
| Biocon Biologics INC | $14.02 | 2024 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trusha Bhatia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.